{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T08:56:35Z","timestamp":1784796995640,"version":"3.55.0"},"reference-count":100,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The blockade of interleukine-1 (anakinra and canakinumab) is a well-known highly effective tool for monogenic autoinflammatory diseases (AIDs), such as familial Mediterranean fever, tumor necrosis factor receptor-associated periodic syndrome, hyperimmunoglobulinaemia D syndrome, and cryopyrin-associated periodic syndrome, but this treatment has not been assessed for patients with undifferentiated AIDs (uAIDs). Our study aimed to assess the safety and efficacy of canakinumab for patients with uAIDs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Information on 32 patients with uAIDs was retrospectively collected and analyzed. Next-generation sequencing and Federici criteria were used for the exclusion of the known monogenic AID.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median age of the first episode was 2.5 years (IQR: 1.3; 5.5), that of the disease diagnosis was 5.7 years (IQR: 2.5;12.7), and that of diagnostic delay was 1.1 years (IQR: 0.4; 6.1). Patients had variations in the following genes: <jats:italic>IL10, NLRP12, STAT2, C8B, LPIN2, NLRC4, PSMB8, PRF1, CARD14, IFIH1, LYST, NFAT5, PLCG2, COPA, IL23R, STXBP2, IL36RN, JAK1, DDX58, LACC1, LRBA, TNFRSF11A, PTHR1, STAT4, TNFRSF1B, TNFAIP3, TREX1<\/jats:italic>, and <jats:italic>SLC7A7<\/jats:italic>. The main clinical features were fever (100%), rash (91%; maculopapular predominantly), joint involvement (72%), splenomegaly (66%), hepatomegaly (59%), lymphadenopathy (50%), myalgia (28%), heart involvement (31%), intestinal involvement (19%); eye involvement (9%), pleuritis (16%), ascites (6%), deafness, hydrocephalia (3%), and failure to thrive (25%). Initial treatment before canakinumab consisted of non-biologic therapies: non-steroidal anti-inflammatory drugs (NSAID) (91%), corticosteroids (88%), methotrexate (38%), intravenous immunoglobulin (IVIG) (34%), cyclosporine A (25%), colchicine (6%) cyclophosphamide (6%), sulfasalazine (3%), mycophenolate mofetil (3%), hydroxychloroquine (3%), and biologic drugs: tocilizumab (62%), sarilumab, etanercept, adalimumab, rituximab, and infliximab (all 3%). Canakinumab induced complete remission in 27 patients (84%) and partial remission in one patient (3%). Two patients (6%) were primary non-responders, and two patients (6%) further developed secondary inefficacy. All patients with partial efficacy or inefficacy were switched to tocilizumab (<jats:italic>n<\/jats:italic> = 4) and sarilumab (<jats:italic>n<\/jats:italic> = 1). The total duration of canakinumab treatment was 3.6 (0.1; 8.7) years. During the study, there were no reported Serious Adverse Events (SAEs). The patients experienced non-frequent mild respiratory infections at a rate that is similar as before canakinumab is administered. Additionally, one patient developed leucopenia, but it was not necessary to stop canakinumab for this patient.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The treatment of patients with uAIDs using canakinumab was safe and effective. Further randomized clinical trials are required to confirm the efficacy and safety.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1257045","type":"journal-article","created":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T13:39:58Z","timestamp":1700055598000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Safety and efficacy of canakinumab treatment for undifferentiated autoinflammatory diseases: the data of a retrospective cohort two-centered study"],"prefix":"10.3389","volume":"10","author":[{"given":"Ekaterina","family":"Alexeeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiri","family":"Shingarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Dvoryakovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Lomakina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fetisova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenia","family":"Isaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Chomakhidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Chibisova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizaveta","family":"Krekhova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Kozodaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirill","family":"Savostyanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandr","family":"Pushkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya","family":"Zhanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Demyanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Suspitsin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Belozerov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Kostik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1016\/j.lpm.2018.12.003","article-title":"Autoinflammatory diseases: State of the art","volume":"48","author":"Georgin-Lavialle","year":"2019","journal-title":"Presse Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"R34","DOI":"10.1186\/ar3266","article-title":"Canakinumab (ACZ885, a fully human IgG1 anti-IL-1\u03b2 mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)","volume":"13","author":"Kuemmerle-Deschner","year":"2011","journal-title":"Arthritis Res Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/1744666X.2017.1324783","article-title":"Canakinumab for the treatment of TNF-receptor associated periodic syndrome","volume":"13","author":"La Torre","year":"2017","journal-title":"Expert Rev Clin Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1093\/rheumatology\/kes097","article-title":"Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency","volume":"51","author":"Galeotti","year":"2012","journal-title":"Rheumatology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3899\/jrheum.100718","article-title":"Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine","volume":"38","author":"\u00d6zen","year":"2011","journal-title":"J Rheumatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1136\/annrheumdis-2015-207701","article-title":"Next-generation sequencing and its initial applications for molecular diagnosis of systemic auto-inflammatory diseases","volume":"75","author":"Rusmini","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"rkz004","DOI":"10.1093\/rap\/rkz004","article-title":"Efficacy and safety of anakinra for undifferentiated autoinflammatory diseases in children: a retrospective case review","volume":"3","author":"Garg","year":"2019","journal-title":"Rheumatol Adv Pract"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1136\/annrheumdis-2018-214472","article-title":"Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases","volume":"78","author":"Ter Haar","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e86336","DOI":"10.1172\/jci.insight.86336","article-title":"Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology","volume":"1","author":"Harrison","year":"2016","journal-title":"JCI Insight."},{"key":"B10","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1136\/annrheumdis-2014-206580","article-title":"Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers","volume":"74","author":"Federici","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/b0-12-369398-5\/00104-3","article-title":"Likert scale analysis","author":"Bernstein","year":"","journal-title":"Encyclop Soc Meas"},{"key":"B13","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.dld.2004.12.009","article-title":"A functional interleukin-10 mutation in Dutch patients with Crohn's disease","volume":"37","author":"van der Linde","year":"2005","journal-title":"Dig Liver Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1002\/1522-2683(200011)21:17<3578::AID-ELPS3578>3.0.CO","article-title":"The IL-10 gene is not involved in the predisposition to inflammatory bowel disease","volume":"21","author":"Klein","year":"2000","journal-title":"Electrophoresis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"109159","DOI":"10.1016\/j.clim.2022.109159","article-title":"In-vitro NLRP3 functional test assists the diagnosis of cryopyrin-associated periodic syndrome (CAPS) patients: A Brazilian cooperation","volume":"245","author":"Mendon\u00e7a","year":"2022","journal-title":"Clin Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00296-018-4002-8","article-title":"Multigene sequencing reveals heterogeneity of NLRP12-related autoinflammatory disorders","volume":"38","author":"Kostik","year":"2018","journal-title":"Rheumatol Int."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s12098-022-04322-w","article-title":"Frightening Fever: Familial Cold Autoinflammatory Syndrome 2 (FCAS-2) with Macrophage Activation Syndrome (MAS)","volume":"89","author":"Pati","year":"2022","journal-title":"Indian J Pediatr."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1002\/art.30241","article-title":"Identification and functional consequences of a recurrent NLRP12 missense mutation in periodic fever syndromes","volume":"63","author":"J\u00e9ru","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B19","doi-asserted-by":"publisher","first-page":"99237","DOI":"10.18632\/oncotarget.18502","article-title":"Comparative analysis of primary versus relapse\/refractory DLBCL identifies shifts in mutation spectrum","volume":"8","author":"Greenawalt","year":"2017","journal-title":"Oncotarget."},{"key":"B20","doi-asserted-by":"publisher","first-page":"9171","DOI":"10.1038\/s41598-019-45598-x","article-title":"Multiple Sclerosis patients carry an increased burden of exceedingly rare genetic variants in the inflammasome regulatory genes","volume":"9","author":"Vidmar","year":"2019","journal-title":"Sci Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"990111","DOI":"10.3389\/fped.2022.990111","article-title":"Case report: The cardio-facio-cutaneous syndrome due to a novel germline mutation in MAP2K1: A multifaceted disease with immunodeficiency and short stature","volume":"10","author":"Szczawi\u0144ska-Pop\u0142onyk","year":"2022","journal-title":"Front Pediatr."},{"key":"B22","doi-asserted-by":"publisher","first-page":"937","DOI":"10.3390\/genes14040937","article-title":"Comprehensive Genetic Analysis of Druze Provides Insights into Carrier Screening","volume":"14","author":"Avnat","year":"2023","journal-title":"Genes (Basel)."},{"key":"B23","doi-asserted-by":"publisher","first-page":"10086","DOI":"10.1038\/ncomms10086","article-title":"Patterns and functional implications of rare germline variants across 12 cancer types","volume":"6","author":"Lu","year":"2015","journal-title":"Nat Commun."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.1038\/s41467-018-05914-x","article-title":"The prognostic effects of somatic mutations in ER-positive breast cancer","volume":"9","author":"Griffith","year":"2018","journal-title":"Nat Commun."},{"key":"B25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13073-016-0333-9","article-title":"The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine","volume":"8","author":"Garofalo","year":"2016","journal-title":"Genome Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"11872","DOI":"10.1073\/pnas.1819825116","article-title":"Gain-of-function mutations in a member of the Src family kinases cause autoinflammatory bone disease in mice and humans","volume":"116","author":"Abe","year":"2019","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1146\/annurev.nutr.012809.104729","article-title":"Lipins: multifunctional lipid metabolism proteins","volume":"30","author":"Csaki","year":"2010","journal-title":"Annu Rev Nutr."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e002561","DOI":"10.1136\/rmdopen-2022-002561","article-title":"Identification of variants in genes associated with autoinflammatory disorders in a cohort of patients with psoriatic arthritis","volume":"8","author":"Atschekzei","year":"2022","journal-title":"RMD Open."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1159658","DOI":"10.3389\/fneur.2023.1159658","article-title":"Multiple genetic variants involved in both autoimmunity and autoinflammation detected in Chinese patients with sporadic Meniere's disease: a preliminary study","volume":"14","author":"Zou","year":"2023","journal-title":"Front Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00251-020-01170-w","article-title":"Genetic analysis of nucleotide-binding leucine-rich repeat (NLR) receptors in multiple sclerosis","volume":"72","author":"Popplewell","year":"2020","journal-title":"Immunogenetics."},{"key":"B31","doi-asserted-by":"publisher","first-page":"11106","DOI":"10.1038\/s41598-022-15279-3","article-title":"Identification of ultra-rare genetic variants in pediatric acute onset neuropsychiatric syndrome (PANS) by exome and whole genome sequencing","volume":"12","author":"Trifiletti","year":"2022","journal-title":"Sci Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"637629","DOI":"10.1155\/2013\/637629","article-title":"Genetics of proteasome diseases","volume":"2013","author":"Gomes","year":"2013","journal-title":"Scientifica (Cairo)."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.3389\/fimmu.2019.01059","article-title":"Mechanisms of inflammation in neutrophil-mediated skin diseases","volume":"10","author":"Marzano","year":"2019","journal-title":"Front Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1002\/cncr.22718","article-title":"Germline mutations of the perforin gene are a frequent occurrence in childhood anaplastic large cell lymphoma","volume":"109","author":"Cannella","year":"2007","journal-title":"Cancer."},{"key":"B35","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13073-015-0244-1","article-title":"Targeted high-throughput sequencing for genetic diagnostics of hemophagocytic lymphohistiocytosis","volume":"7","author":"Tesi","year":"2015","journal-title":"Genome Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1038\/jid.2014.269","article-title":"Variant analysis of CARD14 in a Chinese Han population with psoriasis vulgaris and generalized pustular psoriasis","volume":"134","author":"Qin","year":"2014","journal-title":"J Invest Dermatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.3389\/fimmu.2018.02239","article-title":"Clinical and genetic heterogeneity of CARD14 mutations in psoriatic skin disease","volume":"9","author":"Israel","year":"2018","journal-title":"Front Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"107806","DOI":"10.1016\/j.celrep.2020.107806","article-title":"mTOR signaling and SREBP activity increase FADS2 expression and can activate sapienate biosynthesis","volume":"31","author":"Triki","year":"2020","journal-title":"Cell Rep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00439-018-01966-7","article-title":"Whole-genome sequencing identifies complex contributions to genetic risk by variants in genes causing monogenic systemic lupus erythematosus","volume":"138","author":"Alml\u00f6f","year":"2019","journal-title":"Hum Genet."},{"key":"B40","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1210\/js.2018-00077","article-title":"Structural biology helps interpret variants of uncertain significance in genes causing endocrine and metabolic disorders","volume":"2","author":"Ittisoponpisan","year":"2018","journal-title":"J Endocr Soc."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1038\/mp.2016.24","article-title":"Whole-genome sequencing in multiplex families with psychoses reveals mutations in the SHANK2 and SMARCA1 genes segregating with illness","volume":"21","author":"Homann","year":"2016","journal-title":"Mol Psychiatry."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e101670","DOI":"10.1371\/journal.pone.0101670","article-title":"NCI-60 whole exome sequencing and pharmacological CellMiner analyses","volume":"9","author":"Reinhold","year":"2014","journal-title":"PLoS ONE."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e0137801","DOI":"10.1371\/journal.pone.0137801","article-title":"Low-frequency IL23R coding variant associated with crohn's disease susceptibility in Japanese subjects identified by personal genomics analysis","volume":"10","author":"Onodera","year":"2015","journal-title":"PLoS ONE."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1090120","DOI":"10.3389\/fmed.2022.1090120","article-title":"Genotype-protein phenotype characterization of NOD2 and IL23R missense variants associated with inflammatory bowel disease: A paradigm from molecular modelling, dynamics, and docking simulations","volume":"9","author":"Nasser","year":"2023","journal-title":"Front Med (Lausanne)."},{"key":"B45","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/ajmg.b.32560","article-title":"Mutation intolerant genes and targets of FMRP are enriched for nonsynonymous alleles in schizophrenia","volume":"174","author":"Leonenko","year":"2017","journal-title":"Am J Med Genet B Neuropsychiatr Genet."},{"key":"B46","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3390\/jcm10030481","article-title":"Congenital diarrhea and cholestatic liver disease: phenotypic spectrum associated with MYO5B mutations","volume":"10","author":"Aldrian","year":"2021","journal-title":"J Clin Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/bjd.14003","article-title":"tale of two sisters: identical IL36RN mutations and discordant phenotypes","volume":"174","author":"Rajan","year":"2016","journal-title":"Br J Dermatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s13555-021-00677-8","article-title":"Role of interleukin 36 in generalised pustular psoriasis and beyond","volume":"12","author":"Sugiura","year":"2022","journal-title":"Dermatol Ther (Heidelb)."},{"key":"B49","doi-asserted-by":"publisher","first-page":"107","DOI":"10.5409\/wjcp.v12.i3.107","article-title":"IFIH1 and DDX58 gene variants in pediatric rheumatic diseases","volume":"12","author":"Raupov","year":"2023","journal-title":"World J Clin Pediatr"},{"key":"B50","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1038\/s41598-019-40874-2","article-title":"Biallelic loss-of-function LACC1\/FAMIN mutations presenting as rheumatoid factor-negative polyarticular juvenile idiopathic arthritis","volume":"9","author":"Rabionet","year":"2019","journal-title":"Sci Rep."},{"key":"B51","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ijpam.2020.11.005","article-title":"New or vanishing frontiers: LACC1-associated juvenile arthritis","volume":"8","author":"Al-Mayouf","year":"2021","journal-title":"Int J Pediatr Adolesc Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"36203","DOI":"10.18632\/oncotarget.15874","article-title":"Search for rare protein altering variants influencing susceptibility to multiple myeloma","volume":"8","author":"Scales","year":"2017","journal-title":"Oncotarget."},{"key":"B53","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13045-018-0679-0","article-title":"Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways","volume":"11","author":"Tessoulin","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"8470","DOI":"10.1038\/ncomms9470","article-title":"Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in S\u00e9zary syndrome","volume":"6","author":"Kiel","year":"2015","journal-title":"Nat Commun."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e20200517","DOI":"10.1084\/jem.20200517","article-title":"Pathological RANK signaling in B cells drives autoimmunity and chronic lymphocytic leukemia","volume":"218","author":"Alankus","year":"2021","journal-title":"J Exp Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/humu.20095","article-title":"Enchondromatosis (Ollier disease, Maffucci syndrome) is not caused by the PTHR1 mutation p.R150C","volume":"24","author":"Rozeman","year":"2004","journal-title":"Hum Mutat."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1093\/hmg\/ddn176","article-title":"PTHR1 mutations associated with Ollier disease result in receptor loss of function","volume":"17","author":"Couvineau","year":"2008","journal-title":"Hum Mol Genet."},{"key":"B58","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","article-title":"The JAK-STAT pathway at 30: Much learned, much more to do","volume":"185","author":"Philips","year":"2022","journal-title":"Cell."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1136\/annrheumdis-2021-221754","article-title":"Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset","volume":"81","author":"Saevarsdottir","year":"2022","journal-title":"Ann Rheum Dis."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/hmg\/ddv620","article-title":"Exome arrays capture polygenic rare variant contributions to schizophrenia","volume":"25","author":"Richards","year":"2016","journal-title":"Hum Mol Genet."},{"key":"B61","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41467-019-14144-8","article-title":"Eighty-eight variants highlight the role of T cell regulation and airway remodeling in asthma pathogenesis","volume":"11","author":"Olafsdottir","year":"2020","journal-title":"Nat Commun."},{"key":"B62","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.neurobiolaging.2022.11.013","article-title":"TREX1 pA129fs and pY305C variants in a large multi-ethnic cohort of CADASIL-like unrelated patients","volume":"123","author":"Foddis","year":"2023","journal-title":"Neurobiol Aging."},{"key":"B63","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/ane.13613","article-title":"Genetic analysis reveals novel variants for vascular cognitive impairment","volume":"146","author":"M\u00f6nk\u00e4re","year":"2022","journal-title":"Acta Neurol Scand."},{"key":"B64","doi-asserted-by":"publisher","first-page":"998281","DOI":"10.3389\/fmed.2022.998281","article-title":"Off-label use of canakinumab in pediatric rheumatology and rare diseases","volume":"9","author":"Del Giudice","year":"2022","journal-title":"Front Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"894846","DOI":"10.3389\/fped.2022.894846","article-title":"Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis","volume":"10","author":"Kostik","year":"2022","journal-title":"Front Pediatr."},{"key":"B66","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/rheumatology\/keq218","article-title":"Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients","volume":"50","author":"Miettunen","year":"2011","journal-title":"Rheumatology (Oxford)."},{"key":"B67","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13256-015-0618-4","article-title":"Interleukin-1 receptor antagonist deficiency with a novel mutation; late onset and successful treatment with canakinumab: a case report","volume":"9","author":"Ulusoy","year":"2015","journal-title":"J Med Case Rep."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/art.41624","article-title":"Novel Majeed Syndrome-Causing LPIN2 mutations link bone inflammation to inflammatory M2 macrophages and accelerated osteoclastogenesis","volume":"73","author":"Bhuyan","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1093\/rheumatology\/keaa119","article-title":"New variant in the IL1RN-gene (DIRA) associated with late-onset, CRMO-like presentation","volume":"59","author":"Kuemmerle-Deschner","year":"2020","journal-title":"Rheumatology (Oxford)."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e20180948","DOI":"10.1542\/peds.2018-0948","article-title":"Renal amyloidosis in deficiency of adenosine deaminase 2: successful experience with canakinumab","volume":"142","author":"Kisla Ekinci","year":"2018","journal-title":"Pediatrics."},{"key":"B71","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1136\/annrheumdis-2012-201818","article-title":"Efficacy of anti-IL-1 treatment in Majeed syndrome","volume":"72","author":"Herlin","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B72","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12969-019-0386-6","article-title":"Is fibrodysplasia ossificans progressiva an interleukin-1 driven auto-inflammatory syndrome?","volume":"17","author":"Haviv","year":"2019","journal-title":"Pediatr Rheumatol Online J."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e11208","DOI":"10.7759\/cureus.11208","article-title":"Persistent tenosynovitis, steroid dependency and a hyperpigmented scaly macular rash in a child with juvenile idiopathic arthritis","volume":"12","author":"Papatesta","year":"2020","journal-title":"Cureus."},{"key":"B74","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/art.39407","article-title":"Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab","volume":"68","author":"Grom","year":"2016","journal-title":"Arthr Rheumatol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s10067-015-3004-0","article-title":"Efficacy and safety profile of anti-interleukin-1 treatment in Beh\u00e7et's disease: a multicenter retrospective study","volume":"35","author":"Emmi","year":"2016","journal-title":"Clin Rheumatol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/1756-185X.12732","article-title":"Safety profile of biologic agents for Beh\u00e7et's disease in a multicenter observational cohort study","volume":"20","author":"Cantarini","year":"2017","journal-title":"Int J Rheum Dis."},{"key":"B77","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12969-020-00438-5","article-title":"Failure of anti Interleukin-1 b monoclonal antibody in the treatment of recurrent pericarditis in two children","volume":"18","author":"Signa","year":"2020","journal-title":"Pediatr Rheumatol Online J."},{"key":"B78","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1136\/annrheumdis-2019-eular.5854","article-title":"IL-1 blockade in pediatric recurrent pericarditis: a multicentric retrospective study on the Italian cohort","volume":"17","author":"Caorsi","year":"2019","journal-title":"Pediatr Rheumatol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.3390\/jcm10091963","article-title":"Syndrome of undifferentiated recurrent fever (SURF): an emerging group of autoinflammatory recurrent fevers","volume":"10","author":"Papa","year":"2021","journal-title":"J Clin Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1093\/rheumatology\/keac584","article-title":"Comorbidities and extra-articular manifestations in difficult-to-treat rheumatoid arthritis: different sides of the same coin?","volume":"62","author":"Dey","year":"2023","journal-title":"Rheumatology (Oxford)."},{"key":"B81","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.3390\/jcm10235586","article-title":"associated with myeloid neoplasm and VEXAS syndrome: two differential diagnoses of suspected adult onset Still's disease in elderly patients","volume":"10","author":"Delplanque","year":"2021","journal-title":"J Clin Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/acr.23277","article-title":"Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis","volume":"70","author":"Schulert","year":"2018","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"B83","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1007\/s10067-018-4095-1","article-title":"Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature","volume":"37","author":"S\u00f6nmez","year":"2018","journal-title":"Clin Rheumatol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/25785826.2018.1524105","article-title":"Diagnosis and treatment of autoinflammatory diseases in adults: a clinical approach from rheumatologists","volume":"41","author":"Koga","year":"2018","journal-title":"Immunol Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"956795","DOI":"10.3389\/fimmu.2022.956795","article-title":"Interleukin-6 inhibition in the treatment of autoinflammatory diseases","volume":"13","author":"Koga","year":"2022","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"820586","DOI":"10.3389\/fped.2022.820586","article-title":"The safety and efficacy of tofacitinib in 24 cases of pediatric rheumatic diseases: single centre experience","volume":"10","author":"Kostik","year":"2022","journal-title":"Front Pediatr."},{"key":"B87","doi-asserted-by":"publisher","first-page":"744780","DOI":"10.3389\/fimmu.2021.744780","article-title":"Real-life indications of interleukin-1 blocking agents in hereditary recurrent fevers: data from the JIRcohort and a Literature Review","volume":"12","author":"Vinit","year":"2021","journal-title":"Front Immunol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.amjms.2023.04.008","article-title":"Empiric treatment for persistent fever from suspected autoinflammatory disease: Experience from an undiagnosed diseases program","volume":"366","author":"Shen","year":"2023","journal-title":"Am J Med Sci."},{"key":"B89","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1586\/eci.10.41","article-title":"Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritis","volume":"6","author":"Yokota","year":"2010","journal-title":"Expert Rev Clin Immunol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1056\/NEJMc1301017","article-title":"Tocilizumab for systemic juvenile idiopathic arthritis","volume":"368","author":"De Benedetti","year":"2013","journal-title":"N Engl J Med"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1114207","DOI":"10.3389\/fped.2023.1114207","article-title":"Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data","volume":"11","author":"Alexeeva","year":"2023","journal-title":"Front Pediatr."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/rheumatology\/ket121","article-title":"Failure of tocilizumab treatment in a CINCA patient: clinical and pathogenic implications","volume":"52","author":"Snegireva","year":"2013","journal-title":"Rheumatology (Oxford)."},{"key":"B93","doi-asserted-by":"publisher","first-page":"5360","DOI":"10.3390\/jcm11185360","article-title":"Tocilizumab for the treatment of familial mediterranean fever-a randomized, double-blind, placebo-controlled phase II study","volume":"11","author":"Henes","year":"2022","journal-title":"J Clin Med."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1007\/s00296-015-3305-2","article-title":"Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS)","volume":"35","author":"La Torre","year":"2015","journal-title":"Rheumatol Int."},{"key":"B95","first-page":"71","article-title":"Tocilizumab \u2013 an effective rescue therapy for refractory unclassified autoinflammatory diseases in children","author":"Kuemmerle-Deschner","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s41232-022-00217-7","article-title":"Autoinflammatory disease: clinical perspectives and therapeutic strategies","volume":"42","author":"Kawakami","year":"2022","journal-title":"Inflamm Regen"},{"key":"B97","doi-asserted-by":"publisher","first-page":"e001246","DOI":"10.1136\/rmdopen-2020-001246","article-title":"Mixed results with baricitinib in biologicalresistant adult-onset Still's disease and undifferentiated systemic autoinflammatory disease","volume":"6","author":"Kacar","year":"2020","journal-title":"RMD Open"},{"key":"B98","doi-asserted-by":"publisher","first-page":"905960","DOI":"10.3389\/fimmu.2022.905960","article-title":"Assessment of type I interferon signatures in undifferentiated inflammatory diseases: A Japanese multicenter experience","volume":"13","author":"Miyamoto","year":"2022","journal-title":"Front Immunol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41390-019-0614-2","article-title":"clinical score to guide in decision making for monogenic type I IFNopathies","volume":"87","author":"S\u00f6nmez","year":"2020","journal-title":"Pediatr Res."},{"key":"B100","doi-asserted-by":"publisher","first-page":"908501","DOI":"10.3389\/fmed.2022.908501","article-title":"Development and implementation of the AIDA international registry for patients with undifferentiated systemic autoinflammatory diseases","volume":"9","author":"Della Casa","year":"2022","journal-title":"Front Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1257045\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T13:40:03Z","timestamp":1700055603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1257045\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,15]]},"references-count":100,"alternative-id":["10.3389\/fmed.2023.1257045"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1257045","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,15]]},"article-number":"1257045"}}